Isotechnika Inc. (ISA.TO) announced that its partner, Lux Biosciences, presented preclinical data demonstrating the safety and pharmacokinetics of LX214 as a potential once-daily topical treatment for chronic inflammatory diseases of the eye.
LX214 is a clear, micellar topical formulation of voclosporin, Isotechnika's next-generation calcineurin inhibitor, which is being developed by Lux Biosciences as a potential treatment for such conditions as dry eye syndrome, blepharitis, and atopic keratoconjunctivitis.
For comments and feedback: editorial@rttnews.com